keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/28527039/erratum-to-high-frequency-aflibercept-injections-in-persistent-neovascular-age-related-macular-degeneration
#1
Ilkay Kilic Muftuoglu, Frank F Tsai, Raouf Gaber, Mostafa Alam, Amit Meshi, William R Freeman
No abstract text is available yet for this article.
May 19, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28520639/wrinkled-vascularized-retinal-pigment-epithelium-detachment-prognosis-after-intravitreal-anti-vegf-therapy
#2
Delphine Lam, Oudy Semoun, Rocio Blanco-Garavito, Camille Jung, Diem T Nguyen, Eric H Souied, Gerard Mimoun
BACKGROUND/PURPOSE: Neovascular age-related macular degeneration (nAMD) is frequently associated with vascularized pigment epithelial detachment (v-PED). We observed a peculiar characteristic of v-PED characterized by small lacy folds of the retinal pigment epithelium, appearing as a wrinkled PED (w-PED) on spectral domain optical coherence tomography (SD-OCT). Our purpose was to describe the visual prognosis and number of intravitreal injections in w-PED compared with non-w-PED. METHODS: In this retrospective, case-control series, we reviewed retrospectively medical records of 52 eyes of 51 patients who were consecutively included between November 1 and 30, 2015 with a previous minimum 3-year follow-up...
May 16, 2017: Retina
https://www.readbyqxmd.com/read/28512425/long-term-follow-up-of-polypoidal-choroidal-vasculopathy-secondary-to-angioid-streaks-treated-by-intravitreal-aflibercept-and-ranibizumab
#3
James G Wong, Katherine Yu Qian
PURPOSE: Angioid streaks (AS) are dehiscences in Bruch's membrane that may be idiopathic or associated with numerous systemic illnesses. Polypoidal choroidal vasculopathy (PCV) is an underdiagnosed exudative chorioretinopathy often characterised by serosanguineous detachments of the pigmented epithelium. The use of the anti-VEGF agents ranibizumab and aflibercept in the management of PCV secondary to AS has not been previously documented. We report 3 patients with active PCV secondary to AS, 1 of which had a family history of PCV secondary to AS, not previously reported in the literature...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28499055/sequential-sterile-intraocular-inflammation-associated-with-consecutive-intravitreal-injections-of-aflibercept-and-ranibizumab
#4
Dilraj S Grewal, Tayler Schwartz, Sharon Fekrat
The authors report the unique response of two patients treated for cystoid macular edema (CME) secondary to central retinal vein occlusion (CRVO) who developed sequential episodes of likely sterile inflammatory responses following separate intravitreal injections of aflibercept (Eylea; Regeneron, Tarrytown, NY) and ranibizumab (Lucentis; Genentech, South San Francisco, CA) despite multiple previous uneventful injections for CME secondary to CRVO. Following the twenty-fifth aflibercept and seventh ranibizumab injection, two patients developed an acute inflammatory response, which was treated empirically with intravitreal antibiotics and topical and oral steroids (in Case 2)...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28499051/safety-and-efficacy-of-ziv-aflibercept-in-the-treatment-of-refractory-diabetic-macular-edema
#5
Mohammed Ashraf, Hassan El Kayal, Ahmed A R Souka
BACKGROUND AND OBJECTIVE: To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of refractory diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective case series looking at the safety of ziv-aflibercept in patients with DME refractory to previous anti-vascular endothelial growth factor (VEGF) therapy. Detailed ophthalmologic examination, best-corrected visual acuity, and optical coherence tomography measurements were performed pre-switch, as well as at each monthly follow-up visit...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28497459/author-s-reply-to-comments-to-visual-and-anatomic-outcomes-after-conversion-to-aflibercept-in-neovascular-age-related-macular-degeneration-12-month-results
#6
Kaveh Abri Aghdam, Carsten Framme, Amelie Pielen, Bernd Junker
No abstract text is available yet for this article.
May 10, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28496301/short-term-outcomes-in-patients-with-branch-retinal-vein-occlusion-who-received-intravitreal-aflibercept-with-or-without-intravitreal-ranibizumab
#7
Yoshihito Sakanishi, Ayumi Usui-Ouchi, Kazunori Tamaki, Keitaro Mashimo, Rei Ito, Nobuyuki Ebihara
PURPOSE: The purpose of this study was to determine the short-term outcomes for patients who received intravitreal aflibercept (IVA) with or without intravitreal ranibizumab (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). PATIENTS AND METHODS: Patients received IVA for ME due to BRVO. Patients who initially received IVA were defined as the treatment-naïve group and those who were switched from IVR to IVA after ME recurrence were defined as the switching group...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28496299/response-of-eyes-with-age-related-macular-degeneration-to-anti-vegf-drugs-and-implications-for-therapy-planning
#8
Noriko Miyamoto, Michiko Mandai, Hiroshi Kojima, Takanori Kameda, Masataka Shimozono, Akihiro Nishida, Yasuo Kurimoto
PURPOSE: To evaluate the response to and dependence on aflibercept or ranibizumab in patients with age-related macular degeneration (AMD). METHODS: We retrospectively reviewed AMD patients who received induction therapy with aflibercept or ranibizumab for the following parameters: whether complete resolution of the retinal fluid ("good response") was achieved and whether recurrence was observed within 3 months ("dependent") after the induction treatment. With aflibercept treatment, treatment-naïve eyes with a good response/non-dependence were recommended a pro re nata regimen, and other eyes were recommended a proactive bimonthly regimen, followed by monitoring of visual acuity (VA) for 12 months...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28494920/clinical-efficacy-of-intravitreal-aflibercept-versus-panretinal-photocoagulation-for-best-corrected-visual-acuity-in-patients-with-proliferative-diabetic-retinopathy-at-52-weeks-clarity-a-multicentre-single-blinded-randomised-controlled-phase-2b-non-inferiority
#9
Sobha Sivaprasad, A Toby Prevost, Joana C Vasconcelos, Amy Riddell, Caroline Murphy, Joanna Kelly, James Bainbridge, Rhiannon Tudor-Edwards, David Hopkins, Philip Hykin
BACKGROUND: Proliferative diabetic retinopathy is the most common cause of severe sight impairment in people with diabetes. Proliferative diabetic retinopathy has been managed by panretinal laser photocoagulation (PRP) for the past 40 years. We report the 1 year safety and efficacy of intravitreal aflibercept. METHODS: In this phase 2b, single-blind, non-inferiority trial (CLARITY), adults (aged ≥18 years) with type 1 or 2 diabetes and previously untreated or post-laser treated active proliferative diabetic retinopathy were recruited from 22 UK ophthalmic centres...
May 5, 2017: Lancet
https://www.readbyqxmd.com/read/28492910/effect-of-bevacizumab-vs-aflibercept-on-visual-acuity-among-patients-with-macular-edema-due-to-central-retinal-vein-occlusion-the-score2-randomized-clinical-trial
#10
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Carl C Awh, Derek Y Kunimoto, Dennis M Marcus, John J Wroblewski, Jacqueline King
Importance: Studies have established the efficacy and safety of aflibercept for the treatment of macular edema due to central retinal vein occlusion. Bevacizumab is used off-label to treat this condition despite the absence of supporting data. Objective: To investigate whether bevacizumab is noninferior to aflibercept for the treatment of macular edema secondary to central retinal or hemiretinal vein occlusion. Design, Setting, and Participants: The SCORE2 randomized noninferiority clinical trial was conducted at 66 private practice or academic centers in the United States, and included 362 patients with macular edema due to central retinal or hemiretinal vein occlusion who were randomized 1:1 to receive aflibercept or bevacizumab...
May 9, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28492860/baseline-factors-associated-with-6-month-visual-acuity-and-retinal-thickness-outcomes-in-patients-with-macular-edema-secondary-to-central-retinal-vein-occlusion-or-hemiretinal-vein-occlusion-score2-study-report-4
#11
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Jacqueline King, Andrew N Antoszyk, Mark A Peters, Michael Tolentino
Importance: Macular edema (ME) is the leading cause of decreased visual acuity (VA) associated with retinal vein occlusion (RVO). Identifying factors associated with better outcomes in RVO eyes treated with anti-vascular endothelial growth factor (VEGF) therapy may provide information useful in counseling patients. Objective: To investigate baseline characteristics associated with 6-month VA and central subfield thickness (CST) outcomes in participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)...
May 9, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28490861/efficacy-of-intravitreal-aflibercept-injections-for-japanese-patients-with-polypoidal-choroidal-vasculopathy
#12
Akira Arakawa, Maiko Inoue, Shimpei Sato, Shin Yamane, Kazuaki Kadonosono
PURPOSE: To evaluate the efficacy of intravitreal aflibercept therapy in treatment-naïve Japanese patients with polypoidal choroidal vasculopathy (PCV) using Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores. SUBJECTS AND METHODS: This study was a prospective, nonrandomized, interventional exploratory clinical trial performed in an institutional setting. Patients with PCV were treated with intravitreal aflibercept 2 mg/0.05 mL every 2 months after 3 initial monthly doses, for 1 year...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28489275/recent-drug-therapies-for-corneal-neovascularization
#13
REVIEW
Xinyao Liu, Shurong Wang, Xuanzhong Wang, Jiaming Liang, Yan Zhang
Corneal neovascularization (CNV) is a common pathological change in ocular surface diseases. It is not only the factor that affects vision, but also the main cause for corneal graft failure. Based on the mechanism of CNV, many achievements have been developed to suppress the formation of CNV. There are certain novel drugs such as aflibercept, gold nanoparticles and netrins which provide us with new clues to treat CNV. However, we still need to develop more effective therapeutic drugs. It is of great significance to develop new effective drugs to suppress the occurrence of CNV...
May 10, 2017: Chemical Biology & Drug Design
https://www.readbyqxmd.com/read/28467427/comparison-between-1-year-outcomes-of-aflibercept-with-and-without-photodynamic-therapy-for-polypoidal-choroidal-vasculopathy-retrospective-observation-study
#14
Kei Takayama, Hiroki Kaneko, Keiko Kataoka, Kyoko Hattori, Eimei Ra, Taichi Tsunekawa, Hiroshi Fukukita, Fuminori Haga, Yasuki Ito, Hiroko Terasaki
Polypoidal choroidal vasculopathy (PCV) is characterized by polyp-like choroidal neovascularization and a branching vascular network. Intravitreal aflibercept injection (IAI) or photodynamic therapy (PDT) is used for treatment. We retrospectively compared the 1-year outcomes of IAI monotherapy and its combination with initial PDT for PCV. Twelve eyes with naïve PCV received three IAIs and a single PDT after the first IAI and as needed injection (combination group); 11 eyes with naïve PCV received three IAIs and as needed injections (IAI group)...
2017: PloS One
https://www.readbyqxmd.com/read/28458510/evaluation-of-contrast-sensitivity-and-other-visual-function-outcomes-in-neovascular-age-related-macular-degeneration-patients-after-treatment-switch-to-aflibercept-from-ranibizumab
#15
Donald R Nixon, Nicholas Ap Flinn
PURPOSE: This study evaluated visual function and anatomic and vision-related quality-of-life outcomes in recalcitrant neovascular age-related macular degeneration (AMD) subjects switched to aflibercept (Eylea(®)) from ranibizumab (Lucentis(®)). METHODS: In a single-center study conducted in Barrie, ON, 40 patients with persistent fluid despite previous ranibizumab treatment were switched to aflibercept with 3 consecutive monthly doses. Main outcome measure was mean change from baseline to week 12 in Pelli-Robson contrast sensitivity (CS)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28448655/change-in-diabetic-retinopathy-through-2-years-secondary-analysis-of-a-randomized-clinical-trial-comparing-aflibercept-bevacizumab-and-ranibizumab
#16
Susan B Bressler, Danni Liu, Adam R Glassman, Barbara A Blodi, Alessandro A Castellarin, Lee M Jampol, Paul L Kaufman, Michele Melia, Harinderjit Singh, John A Wells
Importance: Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents. Objective: To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment for DME. Design, Setting, and Participants: Preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME was conducted in 650 participants receiving aflibercept, bevacizumab, or ranibizumab...
April 27, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28445077/effect-of-epiretinal-membranes-on-antivascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration
#17
Han Joo Cho, Jae Min Kim, Hyoung Seok Kim, Dong Won Lee, Chul Gu Kim, Jong Woo Kim
PURPOSE: To evaluate the effect of epiretinal membranes (ERMs), detected with spectral-domain optical coherence tomography (SD-OCT), on the outcome of antivascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD). METHODS: A total of 434 eyes with treatment-naive nAMD were retrospectively included and analyzed. All patients were administered an initial series of 3 monthly loading injections of ranibizumab or aflibercept, followed by further injections as required...
April 26, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28436640/intravitreal-aflibercept-for-patients-with-diabetic-macular-edema-refractory-to-bevacizumab-or-ranibizumab-analysis-of-response-to-aflibercept
#18
Yen-Yi Chen, Pei-Yao Chang, Jia-Kang Wang
PURPOSE: To investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients with diabetic macular edema (DME) refractory to ranibizumab or bevacizumab. DESIGN: A retrospective chart review. METHODS: From September 2013 to March 2016, we identified patients with DME who developed resistance to bevacizumab or ranibizumab. Three monthly intravitreal aflibercept injections were administered in refractory cases...
April 10, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28435211/erratum-prolongation-of-injection-interval-after-switching-therapy-from-ranibizumab-to-aflibercept-in-japanese-patients-with-macular-edema-secondary-to-branch-retinal-vein-occlusion-corrigendum
#19
(no author information available yet)
[This corrects the article on p. 403 in vol. 11, PMID: 28260852.].
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28430321/comments-to-visual-and-anatomic-outcomes-after-conversion-to-aflibercept-in-neovascular-age-related-macular-degeneration-12-month-results
#20
Dan Călugăru, Mihai Călugăru
No abstract text is available yet for this article.
April 20, 2017: European Journal of Ophthalmology
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"